/Medicon_Valley_2016.jpg)
/Clinical_Trials_Update_199_px.gif)
Peter Buhl Jensen
Chief Executive Officer
TopoTarget
pbj(at)topotarget.com
/Peter_Buhl_Jensen.jpg)
Background
Co-founder of TopoTarget. MD University of Copenhagen. Gold Medal, Specialist, internal medicin, Ph.D. in preclinical cancer therapeutics evaluation.
Dr. Jensen has 15 years of management experience in cancer research and translational drug development. He previously served as Chief of The Laboratory of Experimental Medicial Oncology and is a Consultant Medical Oncologist at the National University Hospital, Copenhagen.
Dr. Jensen is a member of the scientific Committee of the Danish Cancer Research Fund and a member of the Danish Lung Cancer Group. He has published more than 80 papers on cancer and its treatment.
Dr. Jensen serves on the boards of Directors of AntiAnthra ApS, LiPlasome A/S, Symbion Fonden and Affibody AB. In 2007 Dr. Jensen was appointed Honorary professor of Clinical Oncology at the University of Copenhagen.